“Role of kidney function and concentrations of BAFF, sPD-L1 and sCD25 on mortality in hospitalized patients with COVID-19”

Ladan Mansouri1*, Senka Sendić2, Sebastian Havervall3, Charlotte Thålin3, Stefan H. Jacobson2 and Joachim Lundahl1

Abstract

Background: Chronic kidney disease (CKD) is a recognized risk factor for severe complications in COVID-19. Our objective was to analyze the association between kidney function / T and B lymphocyte modulatory factors and risk of mortality in COVID-19 patients.

Methods: In-hospital and 30-day mortality were analyzed in COVID-19 patients (n = 110). Plasma levels of selected T and B cell modulators were analyzed and correlated to mortality risk. A subgroup of sex- and eGFR-matched COVID-19 patients was compared to CKD patients without infection and healthy subjects.

Results: COVID-19 patients who died in hospital and within 30 days had significantly higher BAFF and sCD25 plasma levels than survivors. In logistic regression models patients with high BAFF, sCD25 and sPD-L1 levels had significantly higher risk of both in-hospital and 30-day mortality while there was no association to eGFR. In the subgroup analysis, a higher level of BAFF, IFN-α, sCD25, sPD-L1 and a lower level of sCD40L was observed in COVID-19 patients compared to the CKD group with corresponding kidney function.

Conclusions: We demonstrate that kidney function and concentrations of BAFF, sCD25 and PD-L1, independent of previously recognized risk factors; age, male gender, and leukocytosis are associated with risk of in-hospital and 30-day mortality in patients with COVID-19. These data indicate the significance of adaptive immune system modulators in COVID-19 and motivate further analysis to identify new potential prognostic and therapeutic approaches.

Keywords: COVID-19, BAFF, sCD25, SPD-L1, Kidney function

Background

Presence of chronic kidney disease (CKD) has recently emerged as one of the most common risk factors for severe Coronavirus disease (COVID)-19 [1]. Patients with advanced CKD (stages 4–5, estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73m²), dialysis or a kidney transplant are among the groups with the highest risk of death from COVID-19, and notably even after adjustment for covariates. This risk is higher than the risk conferred by for example diabetes, asthma, and chronic heart disease [1–9]. Yet, the increased risk is also evident in moderate CKD (eGFR < 60 ml/min/1.73m²) and even a mild increase in serum creatinine seems to associate with increased risk of severe COVID-19 and mortality [3, 9, 10].

Impairment in the innate and adaptive immune system as well as disturbances in cellular immunity predisposes to an increased risk of severe infections, virus-associated cancers, and a weakened vaccine response in
CKD [11–13]. However, an exaggerated response of the immune systems can also occur in CKD, resulting in increased production and decreased clearance of pro-inflammatory chemokines and cytokines, which in turn leads to systemic inflammation with sequelae [12].

Recent studies have suggested that not only antibodies, but also memory B cells, and specially T cells, have an important role in immunity towards COVID-19 [14, 15]. Vaccination is an important component to retard the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 pandemic, but vaccine protection in CKD may be less effective [11, 12]. The clinical and immunological factors that contribute to the greater vulnerability for severe COVID-19 in CKD, and a potential lower effect of vaccination have not fully been explored and new information may provide valuable insights into new therapeutic approaches.

Given a significant role of the adaptive immune system in the clinical course of COVID-19 and in the outcome of the vaccination program in patients with reduced kidney function, we analyzed selected factors that are involved in B cell function; B cell activating factors (BAFF), Interleukin (IL-4), Interferon (IFN)-α and T cell function: soluble Programmed death-ligand (sPD-L)-1, soluble Cluster of differentiation (sCD)-25, sCD40L, sCD95, and their relation to in-hospital and 30-day mortality in hospitalized patients with COVID-19. Moreover, to expand the knowledge of the impact of reduced kidney function in COVID-19 patients, we included a CKD group that matched a subgroup of COVID-19 patients for sex and eGFR in parallel with a sex- and age-matched healthy control group.

We hypothesized that these inflammatory molecules are affected in COVID-19 patients and are associated to the mortality risk. We also tested the hypothesis that the levels of these denominators were not solely a consequence of reduced kidney function in COVID-19 patients.

**Methods**

**Study population**

One hundred ten COVID-19 patients admitted to Danderyd University Hospital, Stockholm, Sweden were included between April 9 and June 8, 2020. Patients were admitted to hospital at different stages and at different time points of their COVID-19 disease, depending on the different clinical signs and symptoms. Clinical characteristics in a subgroup of these patients have been presented elsewhere [16]. Inclusion criteria were age > 18 years, diagnosis of COVID-19 with reverse-transcriptase polymerase chain reaction (RT-PCR) viral RNA detection of nasopharyngeal or oropharyngeal swabs or clinical presentation, with known kidney function (eGFR). 33 sex- and eGFR-matched patients with mild to severe CKD and 35 healthy sex and age-matched subjects from the PROGRESS study [17] were included as controls (Table 1). The PROGRESS study was a cohort study wherein patients with CKD and matched healthy controls were systematically enrolled to be followed and analyzed under the course of five years. They had no ongoing infection at the time and the plasma samples from these individuals at time of recruitment was used in the current study as controls.

In-hospital mortality and mortality within 30 days from admission (30-day mortality) were obtained from medical records. The portion of patients who had treatment with low molecular weight heparin or glucocorticoids at the time of sampling was 78% and 5% respectively. High doses of steroids, antiviral medication or hydroxychloroquine were not clinically applied during the study period. 32% of the patients had treatment with either an angiotensin-converting-enzyme inhibitor or an angiotensin II receptor blocker. Most patients were hospitalized at a general ward (86%), while 10% of patients were admitted to an intermediate care unit and 4% of patients to the intensive care unit at the time of blood sampling.

**Demographic and laboratory data**

Routine laboratory blood analyses (plasma creatinine, C-reactive protein (CRP), white blood cell (WBC) count, neutrophil count, and lymphocyte count in patients with COVID-19 were performed at the time of admission at the Karolinska University Hospital Laboratory, Stockholm, Sweden. We present both plasma creatinine and estimated glomerular filtration rate (eGFR, CKD-EPI formula) since COVID-19 patients may comprise both patients with CKD and patients with acute kidney injury (AKI), and eGFR may be more accurate in CKD than in AKI. COVID-19 patients had a median eGFR of 84 ml/min/1.73m² which was chosen as a threshold value and the patients with eGFR below this threshold value were regarded having reduced kidney function. We analyzed neutrophil-to-lymphocyte ratio (NLR) in COVID-19 patients (median 4, IQR 2.4–8.0) since it has previously been shown that this ratio is higher in more severe COVID-19 disease and a predictive factor for mortality [18, 19].

**Analysis of circulatory inflammatory factors using multiplex immunoassay**

EDTA tubes (Vacutainer, Becton Dickinson, UK) were applied to collect blood from patients after hospital admission and plasma was prepared by centrifugation at 2,000 × g for 20 min at room temperature and stored in -80 °C freezer. After thawing, the plasma samples were centrifuged at 16,000 × g for 4 min and diluted.
We analyzed the levels of the BAFF, IL-4, sCD25/IL-2Rα, sCD40L, sPD-L1, sCD95/Fas and IFN-α, using the Human Magnetic Luminex Assay premixed 21-plex (Cat-
log nr. LXSAHM-21, Lot nr. L134758, R&D systems, Minnesota, USA). The plates were analyzed by Bio-plex MAGPIX Multiplex reader (Bio Rad, California, USA). A pooled plasma was used for inter-plate comparisons as control.

**Statistical analysis**

Patients with COVID-19 ($n=110$) and patients with CKD (disease controls) ($n=33$) and healthy controls ($n=35$) were compared. We also compared laboratory results in 29 CKD patients (of 33 disease controls) who were matched for kidney function with the subgroup of COVID-19 patients with reduced eGFR (eGFR ≤ 84 ml/ min/1.73m²) as explained earlier. Comparisons between three groups were performed using the nonparametric Kruskal–Wallis test, and comparison between two groups with Mann–Whitney U-test, due to non-normal distribution of results. We applied the Dunn’s post hoc test for multiple comparisons following the Kruskal–Wallis test. Scatter plots were prepared in GraphPad Prism 8.3 (GraphPad Software, Inc., USA) in which whiskers represent 25–75% interquartile range (IQR) and the median is shown by a line. GraphPad Prism 8.3 (GraphPad Software, Inc., USA), STATISTICA version 10 (StatSoft, Inc., USA) and IBM SPSS Statistics 25 (IBM Corp., USA) were applied for statistical analysis. Spearman’s rank correlation test was used to determine the relationship between eGFR and demographic and laboratory data, as well as between cytokines and neutrophil-to-lymphocyte ratio. Chi-square test was applied to analyze differences between stratified groups. Logistic multiple regression analyses were applied for analysis of mortality risk. Due to the low number of patients, we were able to adjust analyses for only one factor at a time. As age has been

### Table 1: Comparison between patients with COVID-19, patients with chronic kidney disease (CKD) and healthy subjects. The comparison between groups was analyzed by nonparametric Kruskal–Wallis test and a $P<0.05$ was considered a significant difference

|                      | COVID-19 ($n=110$) | CKD patients ($n=33$) | Healthy subjects ($n=35$) | $P$ (K-W) |
|----------------------|--------------------|-----------------------|---------------------------|-----------|
|                      | Median IQR 25–75%  | Median IQR 25–75%     | Median IQR 25–75%         |           |
| Age (years)          | 60 50–69           | 55 44.5–58             | 50 39–57                  | <0.001a   |
| BMI$^1$ (kg/m²)      | 28 24.6–31.6       | 25.0 23.5–28.0         | 24 22–27                  | <0.001b   |
| Creatinine (µmol/l)  | 73 57.5–89         | 122 107–160            | 72 66–77                  | <0.001c   |
| eGFR$^2$ (ml/min/1.73m²) | 84 67–90       | 53 40–65               | 102 96–108                | <0.001d   |
| CRP$^3$ (mg/l)       | 99 63–174          | 1.6 0.9–4.3            | 0.89 0.31–2.2             | <0.001e   |
| B cell modulation    |                    |                       |                           |           |
| BAFF$^4$ (pg/ml)     | 824 576–1099       | 448 395–551            | 403 365–449               | <0.001f   |
| IL-4$^5$ (pg/ml)     | 104 88–124         | 134 111–208            | 119 98–156                | <0.001g   |
| IFN-α$^6$ (pg/ml)    | 18.5 9–36.5        | 10 4.5–25              | 8 5–32.5                  | 0.02h     |
| T cell modulation    |                    |                       |                           |           |
| sCD25$^7$/IL-2Rα$^8$ (pg/ml) | 1178 931–1587 | 734 582–808            | 363 309–441               | <0.001i   |
| sCD40L (pg/ml)       | 1515 1220–1884     | 7663 5688–9955         | 7239 4985–9564            | <0.001j   |
| sPD-L1$^9$ (pg/ml)   | 146 96–227         | 83 61–102              | 39 30–48                  | <0.001k   |
| sCD95/Fas (pg/ml)    | 6083 4727–7292     | 8519 7373–10,112       | 5572 4917–6058            | <0.001l   |

$^1$ Body mass index  
$^2$ Estimated glomerular filtration rate  
$^3$ C-reactive protein  
$^4$ B-cell activating factor  
$^5$ Interleukin 4  
$^6$ Interferon-α  
$^7$ Soluble cluster of differentiation 25  
$^8$ Interleukin 2 receptor-α  
$^9$ Soluble programmed death-ligand 1  

$^a$ $P<0.01$ comparing COVID-19 and CKD patients and $P<0.0001$ vs healthy controls, $^b$ $P<0.05$ comparing COVID-19 and CKD patients and $P<0.0001$ vs healthy controls, $^c$ $P<0.0001$ comparing COVID-19 and CKD patients and NS vs healthy controls, $^d$ $P<0.0001$ comparing COVID-19 and CKD patients and vs healthy controls, $^e$ $P<0.0001$ comparing COVID-19 and CKD patients and $P<0.0001$ vs healthy controls, $^f$ $P<0.0001$ comparing COVID-19 vs CKD patients and NS vs healthy controls, $^g$ $P<0.0001$ comparing COVID-19 vs CKD patients and vs healthy controls, $^h$ $P<0.0001$ comparing COVID-19 and CKD patients and NS vs healthy controls, $^i$ $P<0.0001$ comparing COVID-19 vs CKD patients and vs healthy controls, $^j$ $P<0.0001$ comparing COVID-19 and CKD patients and vs healthy controls, $^k$ $P<0.0001$ comparing COVID-19 and CKD patients and NS vs healthy controls.
shown to associate with mortality in several other observational studies, we primarily adjusted our analyses for age, as well as sex and eGFR.

**Results**

**Comparisons of COVID-19 patients with CKD patients and healthy subjects**

Table 1 displays the demographic characteristics and laboratory findings of all the participants. In terms of B cell modulation, the concentrations of BAFF and IFN-α were significantly higher and IL-4 lower in the entire patient group with COVID-19 \((n = 110)\) compared to CKD patients (Table 1). Concerning T cell modulation, sCD25 and sPD-L1 levels were significantly higher, while sCD40L and sCD95 levels were significantly lower in COVID-19 patients compared to both control groups. Demographic and routine laboratory data as well as concentrations of immune modulators in patients with COVID-19, patients with CKD and healthy subjects are shown in Table 1.

Since correlation between neutrophil-to-lymphocyte ratio and BAFF levels in Covid-19 has been reported [20], we analyzed this relationship in our patient group, which was significantly correlated \((r = 0.26, P = 0.01)\). Considering the role of IFNs in production of BAFF in immune cells [21] as well as synergy of BAFF and IL-4 in B cell physiology [22], we analyzed the relationship between IFN-α and BAFF and BAFF and IL-4 (Appendix Fig. 1).

The correlation between sCD25 and sPD-L1 levels, the T cell activator and immune checkpoint, in COVID-19 patients, was significant \((r = 0.37, P < 0.0001)\) as well as the relationship between sCD25 and sCD95 \((r = 0.46, P < 0.0001)\) (Appendix Fig. 1).

**Immune modulators in relation to kidney function in patients with Covid-19**

Correlations by Spearman’s rank test between inflammatory modulators and eGFR are presented in Table 2. There were significant negative correlations between eGFR and neutrophil-to-lymphocyte ratio, BAFF, IL-4, sCD25, sPD-L1 and sCD95 in patients with Covid-19. In COVID-19 patients compared to CKD patients with corresponding eGFR. The differences in IL-4 and sCD95/Fas levels which we observed when comparing the larger groups of patients with COVID-19 \((n = 110)\) and CKD \((n = 33)\), were not observed in this subgroup analysis. Appendix Table 1 displays the differences between the two groups.

**In-hospital mortality and 30-day mortality in patients with COVID-19**

Patients who died in-hospital were more often men \((P < 0.05)\) and deceased patients had significantly higher CRP, WBC count and neutrophil-to-lymphocyte ratio and lower eGFR compared to patients who survived hospital stay (Table 3). Concentrations of BAFF and sCD25 were significantly higher in patients who died during hospital stay with a statistical trend also for sPD-L1 and sCD95.

When evaluating 30-day mortality, patients who died were mainly men \((P < 0.05)\) and deceased patients had higher CRP, higher WBC count, lower lymphocyte count, higher neutrophil-to-lymphocyte ratio, higher BAFF, sCD25 and INF-α levels than patients

### Table 2 Correlation (Spearman’s rank correlation, Spearman’s rho) between eGFR and laboratory findings

| Laboratory Findings | Spearman’s rho |
|--------------------|--------------|
| WBC\(^a\) count \((\times 10^9/l)\) | -0.105 |
| Neutrophil count \((\times 10^9/l)\) | -0.098 |
| Lymphocyte count \((\times 10^9/l)\) | 0.368* |
| NLR\(^b\) | -0.279* |
| B cell modulation | |
| BAFF\(^c\) (pg/ml) | -0.356* |
| IL-4\(^d\) (pg/ml) | -0.311* |
| IFN-α\(^e\) (pg/ml) | -0.055 |
| T cell modulation | |
| sCD25\(^f\)/IL-2Rα\(^g\) (pg/ml) | -0.488* |
| sCD40L (pg/ml) | -0.058 |
| sPD-L1\(^h\) (pg/ml) | -0.445* |
| sCD95/Fas (pg/ml) | -0.430* |

\(^a\) White blood cells  
\(^b\) Neutrophil-leukocyte ratio  
\(^c\) B-cell activating factor  
\(^d\) Interleukin 4  
\(^e\) Interferon-α  
\(^f\) Soluble cluster of differentiation 25  
\(^g\) Interleukin 2 receptor-α  
\(^h\) Soluble programmed death-ligand 1  

Statistical significance: * \(P < 0.01\)
Table 3  Characteristics of patients with COVID-19 who died ($n=15$) in hospital or survived ($n=95$)

| In-hospital outcome | Survived | Deceased | $P$ (Chi-square analysis) |
|---------------------|----------|----------|--------------------------|
|                     | Count   | %        | Count   | %        |            |
| Age (years) Low⁵     | 53      | 56       | 3       | 20       | $=0.01$    |
| (median) High¹       | 42      | 44       | 12      | 80       |            |
| Creatinine (µmol/l)  | Low     | 56       | 59      | 3       | 20         | $<0.01$    |
| (median) High        | 39      | 41       | 12      | 80       |            |
| eGFR² (ml/min/1.73m²)| Low     | 44       | 46      | 12      | 80         | $<0.05$    |
| median High          | 51      | 54       | 3       | 20       |            |
| White blood cells    | Low     | 52      | 55      | 2       | 13         | $<0.01$    |
| (median) High        | 43      | 45       | 13      | 87       |            |
| Neutrophil (x10⁹/l)  | Low     | 46      | 48      | 3       | 20         | $<0.05$    |
| (median) High        | 49      | 52       | 12      | 80       |            |
| Lymphocyte count (x10⁹/l)| Low | 42      | 44      | 9       | 60         | $NS$       |
| (median) High        | 53      | 56       | 6       | 40       |            |
| NLR³ (median) Low    | 46      | 48       | 2       | 13       | $=0.01$    |
| High                 | 49      | 52       | 13      | 87       |            |
| CRP⁵ (mg/l) Low      | 51      | 54       | 3       | 20       | $<0.05$    |
| (median) High        | 44      | 46       | 12      | 80       |            |
| B cell modulation    |         |          |         |          |            |
| BAFF⁶ (pg/ml) Low    | 52      | 55      | 3       | 20       | $=0.01$    |
| (median) High        | 43      | 45       | 12      | 80       |            |
| IL-4⁷ (pg/ml) Low    | 50      | 53      | 5       | 33       | $NS$       |
| (median) High        | 45      | 47       | 10      | 67       |            |
| IFN-α⁸ (pg/ml) Low   | 50      | 53      | 4       | 27       | 0.06       |
| (median) High        | 45      | 47       | 11      | 73       |            |
| T cell modulation    |         |          |         |          |            |
| sCD25⁹/IL-2Rα Low    | 53      | 56      | 2       | 13       | $<0.01$    |
| (pg/ml) High         | 42      | 44      | 13      | 87       |            |
| sCD40L (pg/ml) Low   | 48      | 51      | 7       | 47       | $NS$       |
| (median) High        | 47      | 49       | 8       | 53       |            |
| sPD-L1 (pg/ml) Low   | 51      | 54      | 4       | 27       | 0.052      |
| (median) High        | 44      | 46       | 11      | 73       |            |
| sCD95/Fas (pg/ml) Low| 51      | 54      | 4       | 27       | 0.052      |
| (median) High        | 44      | 46      | 11      | 73       |            |

⁵ Estimated glomerular filtration rate  
⁶ White blood cells  
⁷ Neutrophil-leukocyte ratio  
⁸ C-reactive protein  
⁹ B-cell activating factor  
¹ Interleukin 4  
¹ Interferon-α  
¹ Interleukin 2 receptor-α  
¹ Soluble programmed death-ligand 1  
⁸ Low: lower than median. High: higher than median
### Table 4  Characteristics of patients with COVID-19 who died (n = 12) within 30 days and patients who survived (n = 98) for 30 days

| 30-day outcome                  | Survived | Deceased | \( P \) (Chi-square analysis) |
|--------------------------------|----------|----------|-------------------------------|
|                                | Count    | %        | Count                        | %        |
| Age (years) (median)           |          |          |                              |          |
| Low                            | 53       | 54       | 3                            | 25       | 0.057 |
| High                           | 45       | 46       | 9                            | 75       |         |
| Creatinine (µmol/l) (median)   |          |          |                              |          |
| Low                            | 56       | 57       | 3                            | 25       | <0.05  |
| High                           | 42       | 43       | 9                            | 75       |         |
| eGFR (ml/min/1.73m²) (median)  |          |          |                              |          |
| Low                            | 47       | 48       | 9                            | 75       | 0.077  |
| High                           | 51       | 52       | 3                            | 25       |         |
| WBC (x10⁹/l) (median)          |          |          |                              |          |
| Low                            | 53       | 54       | 1                            | 8        | <0.01  |
| High                           | 45       | 46       | 11                           | 92       |         |
| Neutrophil count (x10⁹/l) (median) |          |          |                              |          |
| Low                            | 48       | 49       | 1                            | 8        | <0.01  |
| High                           | 50       | 51       | 11                           | 92       |         |
| Lymphocyte count (x10⁹/l) (median) |          |          |                              |          |
| Low                            | 42       | 43       | 9                            | 75       | <0.05  |
| High                           | 56       | 57       | 3                            | 25       |         |
| NLR (median)                   |          |          |                              |          |
| Low                            | 48       | 49       | 0                            | 0        | =0.001 |
| High                           | 50       | 51       | 12                           | 100      |         |
| CRP (mg/l) (median)            |          |          |                              |          |
| Low                            | 53       | 54       | 1                            | 8        | <0.01  |
| High                           | 45       | 46       | 11                           | 92       |         |
| BAFF (pg/ml) (median)          |          |          |                              |          |
| Low                            | 53       | 54       | 2                            | 17       | <0.05  |
| High                           | 45       | 46       | 10                           | 83       |         |
| IL-4 (pg/ml) (median)          |          |          |                              |          |
| Low                            | 51       | 52       | 4                            | 33       | NS     |
| High                           | 47       | 48       | 8                            | 67       |         |
| IFN-α (pg/ml) (median)         |          |          |                              |          |
| Low                            | 52       | 53       | 2                            | 17       | <0.05  |
| High                           | 46       | 47       | 10                           | 83       |         |
| sCD25/IL-2Ra (pg/ml) (median)  |          |          |                              |          |
| Low                            | 53       | 54       | 2                            | 17       | <0.05  |
| High                           | 45       | 46       | 10                           | 83       |         |
| sCD40L (pg/ml) (median)        |          |          |                              |          |
| Low                            | 51       | 52       | 4                            | 33       | NS     |
| High                           | 47       | 48       | 8                            | 67       |         |
| sPD-L1 (pg/ml) (median)        |          |          |                              |          |
| Low                            | 52       | 53       | 3                            | 25       | 0.067  |
| High                           | 46       | 47       | 9                            | 75       |         |
| sCD95/Fas (pg/ml) (median)     |          |          |                              |          |
| Low                            | 52       | 53       | 3                            | 25       | 0.067  |
| High                           | 46       | 47       | 9                            | 75       |         |

* Estimated glomerular filtration rate

** White blood cells

\( c \) Neutrophil-leukocyte ratio

\( d \) C-reactive protein

\( e \) B-cell activating factor

\( f \) Interleukin 4

\( g \) Interferon-α

\( h \) Soluble cluster of differentiation 25

\( i \) Interleukin 2 receptor-α

\( j \) Soluble programmed death-ligand 1

\( k \) Low: lower than median.  \( l \) High: higher than median
who survived for 30 days (Table 4). A statistical trend towards higher concentrations for sPD-L1 and sCD95 was also observed in patients who died within 30 days.

**Unadjusted, age-adjusted, sex-adjusted, and eGFR-adjusted risk of in-hospital mortality in patients with COVID-19**

In unadjusted logistic regression analysis of risk of in-hospital mortality, age \((P < 0.01, \text{OR} 1.071, \text{CI} 1.023–1.122)\), eGFR, CRP, WBC count, neutrophil count, neutrophil-to-lymphocyte ratio, BAFF, sCD25 and PDL-1 levels were significantly associated with risk of in-hospital mortality.

Risk of in-hospital mortality in patients with COVID-19, adjusted for age, is shown in Table 5. Patients with high CRP, WBC count, neutrophil-to-lymphocyte ratio and sCD25 had significantly higher risk of in-hospital mortality, with a statistical trend for BAFF. No association to eGFR was observed in the age adjusted model.

An analysis of in-hospital mortality adjusted for sex is shown in Table 5, in which concentrations of BAFF \((P < 0.05)\), sCD25 \((P < 0.05)\) and sPD-L1 \((P < 0.05)\) were significantly associated with mortality. An analysis of in-hospital mortality adjusted for eGFR, showed no cytokine level associated with mortality (Table 5).

**Unadjusted, age-adjusted, sex-adjusted, and eGFR-adjusted risk of 30-day mortality in patients with COVID-19**

In unadjusted logistic regression analysis of 30-day mortality the following parameters were significantly associated with risk of mortality: age \((P < 0.05, \text{OR} 1.052, \text{CI} 1.004–1.102)\), eGFR, CRP, WBC count, neutrophil count, neutrophil-to-lymphocyte ratio, BAFF, sCD25 and sPD-L1.

Variables associated with 30-day mortality with COVID-19, adjusted for age, are shown in Table 6. Patients with high CRP, WBC count, neutrophil count,
neutrophil-to-lymphocyte ratio, BAFF, sCD25 and sPD-L1 had significantly higher risk of 30-day mortality, with no significant association with eGFR. The same analysis adjusted for sex, showed a similar pattern (Table 6), while analysis adjusted for eGFR showed that high BAFF levels associated with increased risk of mortality (P < 0.05), (Table 6).

**Discussion**

Our main finding in the present study is that kidney function and factors that are partly involved in B cell activation (BAFF), T cell activation (sCD25) and suppression (sPD-L1), apart from previously recognized risk factors; age, male gender, leukocytosis, and high neutrophil-to-lymphocyte ratio are associated with risk of mortality and add important predictive information in hospitalized patients with COVID-19.

In the present study we included a CKD group without COVID-19 infection that was sex- and eGFR-matched with a subgroup of COVID-19 patients with reduced kidney function together with a healthy control group. The rationale for this design was to evaluate whether patients with impaired kidney function during COVID-19, an acute infection, exhibit a cytokine signature different from that in matched CKD patients, with a chronic systemic inflammatory state, but without an acute COVID-19 infection. Indeed, the observed differences between the entire COVID-19 group and the control groups persisted when we compared the subgroup of COVID-19 patients with CKD patients with similar kidney function. This denotes that the immune signature that associates with mortality, is not exclusive for COVID-19 patients with kidney impairment and should be regarded as a risk feature regardless of kidney function. It is however important to mention some patients with COVID-19 may have had a concurrent episode of AKI which may have influenced the results. We report that the level of BAFF, a cytokine important for activation, development, and proper selection of B cells, associates with mortality in COVID-19.

### Table 6

|                        | Age-adjusted | Sex-adjusted | eGFR-adjusted |
|------------------------|--------------|--------------|---------------|
|                        | P-value      | OR 95% CI    | P-value       | OR 95% CI    | P-value       | OR 95% CI    |
| s-Creatinine (µmol/l)  | NS 1.000     | 0.994–1.006  | NS 1.001      | 0.995–1.007  | -             | -             |
| eGFRa (ml/min/1.73m²) | NS 0.983     | 0.955–1.012  | = 0.010       | 0.969        | 0.946–0.993   | -             | -             |
| CRPb (mg/l)            | = 0.001      | 1.012        | < 0.01        | 1.011        | 1.004–1.019   | = 0.001       | 1.011        | 1.004–1.019   |
| WBC count (x10⁹/l)    | < 0.001      | 1.435        | < 0.001       | 1.464        | 1.190–1.800   | = 0.001       | 1.331        | 1.122–1.579   |
| Neutrophil count (x10⁹/l) | < 0.001   | 1.589        | < 0.001       | 1.626        | 1.243–2.128   | = 0.000       | 1.613        | 1.237–2.103   |
| Lymphocyte count (x10⁹/l) | NS 0.498   | 0.126–1.964  | NS 0.455      | 0.125–1.656  | NS 0.562      | 0.146–2.157   |
| NLRd                   | = 0.01       | 1.155        | = 0.01        | 1.151        | 1.033–1.283   | = 0.01        | 1.158        | 1.031–1.301   |

**B cell modulation**

- BAFFe (pg/ml) < 0.05 1.001 1.000–1.002 0.01 1.001 1.000–1.002 < 0.05 1.001 1.000–1.002
- IL-4f (pg/ml) NS 1.005 0.996–1.014 NS 1.003 0.995–1.011 NS 1.003 0.995–1.011
- IFN-αg (pg/ml) NS 1.005 0.997–1.014 NS 1.003 0.995–1.011 NS 1.004 0.995–1.012

**T cell modulation**

- sCD25h/IL-2Rαi (pg/ml) < 0.05 1.000 1.000–1.001 < 0.05 1.001 1.000–1.001 NS 1.000 1.000–1.001
- sCD40L (pg/ml) NS 1.000 0.999–1.001 NS 1.000 0.999–1.001 NS 1.000 1.000–1.001
- sPD-L1j (pg/ml) < 0.05 1.005 1.000–1.009 < 0.05 1.005 1.001–1.010 NS 1.004 0.998–1.009
- sCD95 (pg/ml) NS 1.000 1.000–1.000 NS 1.000 1.000–1.000 NS 1.000 1.000–1.000

*a* Estimated glomerular filtration rate  
*b* C-reactive protein  
*c* White blood cells  
*d* Neutrophil-leucocyte ratio  
*e* B-cell activating factor  
*f* Interleukin 4  
*g* Interferon-α  
*h* Soluble cluster of differentiation 25  
*i* Interleukin 2 receptor-α  
*j* Soluble programmed death-ligand 1
and that B cells do a major role in SARS-CoV-2 infection due to their rapid production of neutralizing antibodies [23, 24]. However, it is noteworthy that BAFF is not only a major B cell modulator but also modifies other immune cells such as T cells [25].

The production of BAFF is associated with type I IFNs when viruses, including SARS-CoV-2, invade cells such as monocytes, macrophages, and dendritic cells [22, 25, 26] but there are heterogeneous IFN-α profiles reported in COVID-19 patients [26, 27]. Herein, we report a higher level of IFN-α compared to our two control groups but without any clear association with mortality.

Since disturbances in the T cell compartment characterize COVID-19 patients [28] and different subpopulations are proposed to predict the clinical course of the disease [29, 30], we focused on two factors related to T cell function in our study, namely sCD25/IL-2Ra (activation) and sPD-L1 (immune-checkpoint). We report an association between sCD25 levels and both in-hospital and 30-day mortality in COVID-19 patients, together with higher plasma levels compared to CKD patients and healthy controls. Soluble CD25 is generated upon activation, binds to IL-2 and can thus modulate the immune responses [31, 32]. The level has been reported to be higher in severely ill patients [33], higher compared to healthy controls [34] and may reflect the divergence in T cell responses, anti-virus and pro-inflammatory responses [35].

The sPD-L1 level was associated with mortality and was increased in COVID-19 patients compared to both healthy controls and the matched subgroup of CKD patients without COVID-19. Soluble PD-L1 levels are reported to be higher in active SARS-CoV-2 infection [20] and treatment with anti PD-L1 antibodies restores the T cell capacity to reduce the viral load [31]. Soluble PD-L1 is generally regarded as an immune suppressor factor and check point molecule which has been shown to correlate to the higher plasma viral RNA load in COVID-19 patients [32]. Together, current data indicate a potential role for so-called immune checkpoints in the pathogenesis of COVID-19 and thus also as a potential treatment target [36].

Interestingly, we observed significant correlations between sPD-L1 and sCD25 as well as between sCD95 and sCD25. These associations support a present operational imbalance between T cell suppression and activation in COVID-19 patients. Yet, the interpretation should be made with caution due to the complexity of the immune response network with several redundances and compartment related functions.

Our study has limitations. We have included a relatively small patient sample size and we lack exact knowledge about the cause for the increase in plasma creatinine at the time of sampling. This may be due to SARS-CoV-2 infection with AKI, preexisting CKD, dehydration due to fever/gastrointestinal symptoms or acute hemodynamic instability. We have no information about a possible co-infection or superinfection with bacteria which may affect the immune response in patients with SARS-CoV-2 infection. Moreover, we could not adjust for all three parameters age, sex, eGFR at once for analysis of the mortality risk due to low number of events. Covid-19 is a disease with an individual course, and we cannot state at which exact stage of disease the samples were drawn. This should be kept in mind since the time point for inclusion was based on the clinical need for hospitalization, and not on laboratory parameters. Our study has several strengths, such as an early enrollment and blood sampling of patients at time of admission with systematic recording of patient information, level of care and treatments. Furthermore, this study was performed on treatment-naive patients who were hospitalized early during the first pandemic wave when there were no established treatment recommendations (e.g. anticoagulants and high doses steroids) available. This is important when studying immune system features. Moreover, we compared a subgroup of patients with COVID-19 to sex- and eGFR-matched controls, which has not been reported earlier.

Conclusion
In conclusion, we confirm a significant impact of impaired kidney function on mortality in patients with COVID-19 and add new important information on the influence of increased levels of BAFF, sCD25 and sPD-L1 on the mortality risk. Our data warrants additional analysis to identify new prognostic and therapeutic approaches.

Abbreviations
AKI: Acute kidney injury; BAFF: B cell activating factors; CD: Soluble Cluster of differentiation; CKD: Chronic kidney disease; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; COVID: Coronavirus disease; CRP: C-reactive protein; ETA: Ethylenediaminetetraacetic acid; eGFR: Estimated glomerular filtration rate; IFN: Interferon; IL: Interleukin; IQR: Interquartile range; NLR: Neutrophil-to-lymphocyte ratio; RT-PCR: Reverse-transcriptase polymerase chain reaction; SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus-2; sPD-L: Soluble Programmed death-ligand; WBC: White blood cell.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12882-022-02924-2.

Additional file 1.

Acknowledgements
We would like to thank Fredrik K Johansson, at the Unit for Medical Statistics, Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm for assisting us in the statistical analyses with regards to
logistic regression tests. We also thank Lena Gabrielson, research nurse at Danderyd Hospital, for patient recruitment and sample preparation.

Authors’ contributions
SJ, JL, CT have contributed to conceptualization, CT, SH, LM have contributed to Data curation and LM, SS performed formal data analysis. SJ, JL, LM, SS, CT, SH contributed to validation, drafting, and revising the article, intellectual content. All authors read and approved the final manuscript.

Funding
Open access funding provided by Karolinska Institute. This study was supported by the Knut and Alice Wallenberg foundation, SciLifeLab, Region Stockholm (ALF project 20200276), and Jonas and Christina af Jochinck Foundation.

Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate
The study complied with the Declaration of Helsinki, and informed consent was obtained from all healthy individuals and patients, or in the case of incapacity from their next of kin. The protocol was approved by the Stockholm Ethical Review Board (COMMUNITY study, Dnr 2020–0653).

Consent for publication
Not applicable.

Competing interests
None of the authors have any disclosures to report.

Author details
1 Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden. 2 Division of Nephrology, Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden. 3 Division of Internal Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd University Hospital, Stockholm, Sweden.

Received: 28 November 2021 Accepted: 24 August 2022

Published online: 02 September 2022

References
1. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430–6.
2. Ortiz A, Cozzolino M, Fisler D, Fouque D, Gourmenos D, Massy ZA, et al. Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA. Nephrol Dial Transplant. 2021;36(1):87–94.
3. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–38.
4. Sjostrand M, Johansson A, Aqrawi L, Olsson T, Wahren-Herlenius M, Espi-filter. J Immunol. 2020;196(1):91–6.
5. Hillbrands LB, Duivenvoorden R, Vant P, Franssen CFM, Hemmelder MH, Jager KJ, et al. COVID-19 related mortality in kidney transplant and dialysis patients: results of the BRACODA collaboration. Nephrol Dial Transplant. 2020;35(11):1973–83.
6. Juno JA, Tan HX, Lee WS, Reynolds A, Kelly HG, Wragg K, et al.Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020;26(9):1428–34.
7. Rosell A, Havervall S, von Meijenfeldt F, Hisada Y, Aguilera K, Grover SP, et al. Patients with COVID-19 have elevated levels of circulating extracellular vesicle tissue factor activity that is associated with severity and mortality. Arterioscler Thromb Vasc Biol. 2020;41(2):120315547.
8. Mohamed NE, Benn EKT, Astha V, Okhawere KE, Korn TG, Nkemdirim W, et al. Association between chronic kidney disease and COVID-19-related mortality in New York. World J Urol. 2021;1–7.
9. Liu YF, Zhang Z, Pan XL, Xing GL, Zhang Y, Liu ZS, et al. The chronic kidney disease and acute kidney injury involvement in COVID-19 pandemic: a systematic review and meta-analysis. PLoS ONE. 2021;16(1):e0244779.
10. Holman N, Knighton P, Kar P, O’Keeffe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823–33.
11. Reddy S, Chittur C, Vee J. Vaccination in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):72–8.
12. Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):118–15.
13. Girmid M, Sester U, Sester M, Kaul H, Köhler H. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999;14(12):2807–10.
14. Grifoni A, Weiskopf D, Ramirez SJ, Mateus J, Dan JM, Modderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–501.e15.
15. Mutinelli-Szymanski P, Hude I, Merle E, Lombardi Y, Sersi P, Abtahi M, et al. Neutrophil lymphocyte ratio predicts short-term outcome of COVID-19 in haemodialysis patients. Clin Kidney J. 2021;14(1):124–31.
16. Schultheiss C, Paschold L, Simnica D, Mohme M, Wilscher E, von Wenserski L, et al. Next-generation sequencing of T and B cell receptor repertoires from COVID-19 patients showed signatures associated with severity of disease. Immunity. 2020;53(2):442–55.e4.
17. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY). 2020;370(6520):eabd4250.
18. Juno JA, Tan HX, Lee WS, Reynolds A, Kelly HG, Wragg K, et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med. 2020;26(9):1428–34.
19. Scagnolari C, Pierangeli A, Frasca F, Bitossi C, Viscido A, Oliveto G, et al. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999;14(12):2807–10.
20. Scagnolari C, Pierangeli A, Frasca F, Bitossi C, Viscido A, Oliveto G, et al. Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant. 1999;14(12):2807–10.
21. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY). 2020;370(6520):eabd4250.
22. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY). 2020;370(6520):eabd4250.
23. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY). 2020;370(6520):eabd4250.
24. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY). 2020;370(6520):eabd4250.
25. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY). 2020;370(6520):eabd4250.
26. Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, et al. Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science (New York, NY). 2020;370(6520):eabd4250.
29. Liu L, Chen Z, Du Y, Gao J, Li J, Deng T, et al. CD8(+) T cells predicted the conversion of common COVID-19 to severe. Sci Rep. 2021;11(1):2169.

30. Rezaei M, Majani M, Mahmoudi S, Mortaz E, Mansouri D. Dynamic Changes of Lymphocyte Subsets in the Course of COVID-19. Int Arch and Immunol. 2021;1–9.

31. Pickles DJ, Lee LYW, Starkey T, Freeman-Mills L, Olsson-Brown A, Cheng V, et al. Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome? Br J Cancer. 2020;123(5):691–3.

32. Bermejo-Martin JF, González-Rivera M, Almansa R, Micheloud D, Tedim AP, Domínguez-Gil M, et al. Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19. Critical care (London, England). 2020;24(1):691.

33. Ueland T, Heggelund L, Lind A, Holten AR, Tonby K, Michelsen AE, et al. Elevated plasma sTIM-3 levels in patients with severe COVID-19. J Allergy Clin Immunol. 2021;147(1):92–8.

34. Osman M, Faridi RM, Shigl W, Shabani-Rad MT, Dharmani-Khan P, Parker A, et al. Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Adv. 2020;4(20):5035–9.

35. Xie M, Yunis J, Yao Y, Shi J, Yang Y, Zhou P, et al. High levels of soluble CD25 in COVID-19 severity suggest a divergence between anti-viral and pro-inflammatory T-cell responses. Clinical & translational immunology. 2021;10(2): e1251.

36. Vivarelli S, Falzone L, Torino F, Scandurra G, Russo G, Bordonaro R, et al. Immune-checkpoint inhibitors from cancer to COVID-19: a promising avenue for the treatment of patients with COVID-19 (review). Int J Oncol. 2021;58(2):145–57.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.